Evidence map›Paper›PMID 42182957›Full record

ArticleResearch (Washington, D.C.)2026

An Ex Vivo Patient-Derived Tumor-Bearing Human Kidney Model Recapitulates Drug Toxicity and Metabolic Distribution.

Yaowei Li, Zhe Wang, Qi Liu, Ziyi Liu, Haonan Li, Haiqiang Duan, Shiyu Huang, Qing Shi, Yubo Zhao, Jiaqian Xu and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yaowei LiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0001-9430-2904
Zhe WangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Qi LiuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0002-1439-4293
Ziyi LiuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0003-3309-1906
Haonan LiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0004-3826-1190
Haiqiang DuanNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0000-6339-5132
Shiyu HuangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0001-7456-1965
Qing ShiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0004-6843-956X
Yubo ZhaoNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0006-5950-3974
Jiaqian XuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Tianxi YuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0007-2335-2964
Guangzheng WuNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0003-3551-5258
Hongjian SongNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0000-1273-1028
Changhao ZhaoNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.
Yishuo YanNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0007-8223-7894
Zhishuai ZhangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0002-1554-736X
Zongzheng YangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0004-5350-9043
Zhihao YinNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0002-2547-7759
Jianwei WangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0009-1600-6339
Peng ZhangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0006-0143-8604
Peng DaiNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0009-0002-5600-9963
Dayong HouNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0002-7567-8663
Zhichao TongNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0002-2044-5037
Ziqi WangNHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0002-1933-1876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal metabolic behavior constitutes a critical evaluation parameter during drug development, toxicity assessment, and biodistribution. However, the inherent biological architecture of existing animal and cell-based models fails to recapitulate the authentic metabolic processes and spatial distribution patterns of drugs in the human kidney at a macroscopic level. Therefore, developing a standardized human-derived kidney model was necessary. In this work, the ex vivo tumor-bearing kidney (ETK) model was established using kidneys from 50 clinically diagnosed patients after the radical surgery. The standardized ETK model included the following: (a) selected according to the proportion of preserved normal tissue, vascular status suitable for ETK perfusion, and overall structural integrity of the kidneys; (b) surgical preparation exposed the renal pelvis and enabled catheterization of the renal artery and ureter; (c) perfused with hypothermic (4 to 10 °C) saline at a flow rate of 70 ml/min within perfusion system; and (d) ETK detection efficiency and drug biodistribution were assessed using biological sample indicators. Results showed that ETK maintained intact glomerular and tubular microstructures throughout perfusion and produced stable urine output with preserved filtration capacity. When treated with different kinds of nephrotoxic agents (cisplatin, gentamicin, and cephalosporins), the ETK model reproduced drug-specific injury patterns and exhibited biochemical changes and histological features that were consistent with real clinical observations. In drug-distribution analysis, indocyanine green (ICG) showed a negative fluorescence tumor contrast and enriched fluorescence in the normal kidney in the ETK model, which were consistent with real clinical observations, whereas mouse orthotopic renal cancer models showed positive ICG tumor accumulation, indicating species-dependent differences in renal drug distribution. Overall, the ETK model provided a structurally preserved and functionally responsive human-derived renal system for investigating renal drug metabolism, nephrotoxicity, tumor imaging, and drug-delivery strategies.

Identifiers

PMID42182957
PMCPMC13191094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.